A Study of DTC in Patients With AIDS and AIDS Related Complex

Institut Mérieux

Status: Completed

Conditions: HIV Infections

Treatments: Drug: Ditiocarb sodium

Study type: Interventional

Funder types: Industry

Identifiers

NCT00002069

010A

Details and patient eligibility

About

To determine if ditiocarb sodium (sodium diethyldithiocarbamate; DTC) restores immune and host defense function; if DTC ameliorates the AIDS related complex (ARC) symptoms in patients with AIDS and ARC; if DTC prevents progression from ARC to AIDS or progression of AIDS; and if DTC prolongs survival in AIDS.

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria

Concurrent Medication:

Allowed:

• Zidovudine (AZT).

Exclusion Criteria

Co-existing Condition:

Patients with the following are excluded:

• Active opportunistic infection or progressive Kaposi's sarcoma (KS).
• Dementia.
• Lymphoma.

Concurrent Medication:

Excluded within 3 weeks of study entry:

• Other experimental AIDS therapy.

Patients with the following are excluded:

• Active opportunistic infection or progressive Kaposi's sarcoma (KS).

Patients must be either HIV seropositive or have AIDS or AIDS related complex (ARC) and have life expectancy of at least 6 months.